Tabernanthalog is one of the most exciting compounds to emerge from modern psychedelic neuroscience. Engineered as a safer, non-hallucinogenic analogue of ibogaine, it is rapidly gaining attention across addiction research, neuroplasticity studies, and clinical development. If you are a researcher or laboratory professional looking to explore tabernanthalog effects in a controlled scientific setting, this page covers everything you need to know.

Buy Tabernanthalog — Research-Grade TBG Powder

Our tabernanthalog powder is available in research-grade purity, batch-tested, and supplied with documentation to support your laboratory work. We stock consistent quantities to meet both small-scale and bulk research needs.

When you buy tabernanthalog from us, you receive:

• Verified high-purity TBG powder
• Certificate of Analysis (CoA) on request
• Discreet, secure laboratory packaging
• Reliable and consistent supply
• Bulk pricing for institutions and licensed labs

Tabernanthalog Buy Online — Fast, Reliable Supply

Finding a trustworthy source matters in research. We make it simple to buy tabernanthalog online with transparent product documentation, responsive support, and fast order processing. All purchases are intended strictly for licensed laboratory and research use in compliance with applicable regulations.

Tabernanthalog Delix Therapeutics  

Tabernanthalog was originally developed by Delix Therapeutics, a biotechnology company focused on next-generation psychoplastogens compounds that promote neuroplasticity without inducing hallucinations. Delix Therapeutics engineered TBG specifically to capture the therapeutic potential of ibogaine while eliminating its most significant safety concerns, including cardiotoxicity and prolonged dissociative effects.

Tabernanthalog Dosage — What Research Shows

Preclinical studies have used varying dose ranges to assess tabernanthalog dosage thresholds in animal models. Key findings include:

• Low to moderate doses have demonstrated significant reductions in alcohol- and heroin-seeking behavior in rodent models
• Single-dose administration has shown effects lasting several days, suggesting long-lasting neuroplastic changes
• TBG does not appear to produce conditioned place preference, indicating low abuse potential at studied doses
• No significant cardiac QT prolongation has been observed at research doses, unlike ibogaine

Tabernanthalog Effects — What Makes TBG Unique

Understanding tabernanthalog effects is central to why this compound has attracted so much scientific interest. Unlike ibogaine, which produces powerful and prolonged hallucinogenic experiences, TBG was specifically designed to be non-hallucinogenic while retaining the neuroplasticity-promoting and anti-addictive properties of iboga-class alkaloids.

Anti-Addictive Effects

TBG has significantly reduced self-administration of opioids and alcohol in animal studies. Researchers believe this occurs through the compound’s action on sigma receptors and its ability to promote structural neural plasticity in addiction-related brain circuits.

Neuroplasticity Promotion

One of the most remarkable tabernanthalog effects is its ability to stimulate the growth of dendritic spines and synaptic connections a property known as psychoplastogenicity. This makes TBG highly relevant to research on depression, PTSD, and trauma recovery.

Antidepressant-Like Activity

Animal models have shown rapid and sustained antidepressant-like effects following TBG administration, comparable in speed to ketamine but through a distinct mechanism of action.

Non-Hallucinogenic Profile

Unlike classic psychedelics, TBG does not activate the 5-HT2A receptor pathway responsible for hallucinations. This property makes it easier to study in behavioral models and positions it as a strong candidate for future therapeutic development.

Tabernanthalog Experience  

While no human tabernanthalog experience data is yet available outside of clinical trial settings, preclinical observations paint an encouraging picture. Animal subjects show reduced anxiety-like behavior, decreased drug-seeking, and improved stress resilience following TBG administration without the sedation or dissociation seen with ibogaine or ketamine.

Tabernanthalog DLX-007 Clinical Trial  

The most advanced human research on TBG is being conducted under the designation DLX-007 by Delix Therapeutics. The tabernanthalog DLX-007 clinical trial represents a landmark step in translating preclinical iboga analogue research into human medicine.

Key highlights of the DLX-007 program:

• Phase I clinical trials have been initiated to assess safety, tolerability, and pharmacokinetics in healthy human volunteers
• The trial is designed to evaluate TBG’s non-hallucinogenic profile in humans, validating what was observed in animal models
• DLX-007 is being developed as a potential treatment for alcohol use disorder and opioid use disorder
• Delix Therapeutics has secured significant venture funding to advance the tabernanthalog DLX-007 clinical trial through multiple phases

Tabernanthalog Legal

The tabernanthalog legal status is an important consideration for researchers and buyers. As of 2026:

• Tabernanthalog is not a scheduled substance in the United States, the European Union, or most other jurisdictions
• It is not listed under the UN Convention on Psychotropic Substances
• It is classified as a research chemical, meaning it is legal to purchase and possess for legitimate scientific and laboratory purposes in most countries
• Buyers are solely responsible for verifying the tabernanthalog legal status in their specific country, state, or region before purchasing

Product Specifications

Chemical data